A metabolite derived from the airway microbiome, indole-3-acetic acid (IAA), could become a potential therapeutic candidate for chronic obstructive pulmonary disease (COPD). Researchers at South China Normal University (SCNU) have shown how IAA prevents lung function decline by reducing inflammation, apoptosis and emphysema through IL-22 in the interaction between macrophages and alveolar epithelial cells. Read More
The prognostic role of complement inhibitor CSMD1 was assessed in 1,507 patients with glioma from three different datasets. Results of the bioinformatical analysis suggested that high expression of CSMD1 was associated with increased overall survival and disease-free survival, as well as lower tumor grade. Read More
Applied Pharmaceutical Science Inc. has described new proto-oncogene tyrosine-protein kinase receptor Ret, (V804M mutant) and (G810R mutant) inhibitors reported to be useful for the treatment of cancer and irritable bowel syndrome. Read More
Researchers from Biomea Fusion Inc. presented preclinical data for the novel covalent menin inhibitor, BMF-219, after being evaluated in models of diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Read More
Shanghai Apeiron Biotechnology Co. Ltd. has disclosed triheterocyclic compounds acting as protein mono-ADP-ribosyltransferase TIPARP inhibitors and thus reported to be useful for the treatment of cancer. Read More
Yaoya Technology (Shanghai) Co. Ltd. has disclosed tyrosine-protein kinase BTK inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, lupus erythematosus, lupus nephritis, multiple sclerosis, asthma and Sjogren's syndrome. Read More
GI Cell Inc. has entered into a research and development collaboration for allogeneic chimeric antigen receptor (CAR)-natural killer (NK) candidates with HK Inno.N Corp. Read More
Chimeric antigen receptor (CAR) T-cell therapy is effective in the treatment of multiple myeloma (MM), but its toxicity and complex manufacturing limit their broad use. Read More
Researchers from CSL Behring LLC have investigated the inhibitory properties of an rFc hexamer, named Fc-muTP-L309C, as a modulator of the classic component pathway activation. Read More
The structure of a potent and selective TYK2 inhibitor, NDI-034858 (NTX-973), which was found clinically effective in autoimmune and inflammatory diseases, was disclosed for the first time by researchers from Nimbus Therapeutics LLC. Read More
Stemcyte Inc. has received IND approval from the FDA for a phase II trial using umbilical cord blood stem cell therapy for post-COVID syndrome, or long COVID. Read More
Immunoprecise Antibodies Ltd.'s Polytope TATX-03 antibody combination therapy has been shown to neutralize SARS-CoV-2 variants of concern, including the omicron BA.5 subvariant, in an authentic virus assay. Read More
Tranquis Therapeutics Inc. has announced preclinical data on the antiaging effects of TQS-168, a small-molecule modulator of PGC-1alpha (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha). Read More
